These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35693043)

  • 1. Imaging response assessment for oncology: An algorithmic approach.
    Ruchalski K; Dewan R; Sai V; McIntosh LJ; Braschi-Amirfarzan M
    Eur J Radiol Open; 2022; 9():100426. PubMed ID: 35693043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
    Wahl RL; Jacene H; Kasamon Y; Lodge MA
    J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma.
    Kishikawa T; Suzuki M; Takemoto N; Fukusumi T; Michiba T; Hanamoto A; Tanaka H; Tatsumi M; Isohashi F; Seo Y; Tamari K; Ogawa K; Inohara H
    Head Neck; 2021 Apr; 43(4):1184-1193. PubMed ID: 33368784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
    Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
    J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
    Min SJ; Jang HJ; Kim JH
    Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
    Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Maruyama M; Minami T; Yokoi T; Kuribayashi K; Kijima T; Hashimoto M; Hasegawa S; Yamakado K
    Nucl Med Commun; 2020 Aug; 41(8):790-799. PubMed ID: 32516245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
    Xu J; Li Y; Xie L; Sun X; Cai Z; Wang S; Wang Q; Sun K; Guo W
    Ann Nucl Med; 2022 Jun; 36(6):553-561. PubMed ID: 35380350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
    Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
    Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging biomarkers for evaluating tumor response: RECIST and beyond.
    Ko CC; Yeh LR; Kuo YT; Chen JH
    Biomark Res; 2021 Jul; 9(1):52. PubMed ID: 34215324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
    Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
    Nagoya J Med Sci; 2018 May; 80(2):183-197. PubMed ID: 29915436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
    Kyriazoglou A; Jespers P; Vandecavaye V; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Zaffaroni F; Litière S; Nzokirantevye A; Schöffski P
    Acta Oncol; 2022 Jun; 61(6):663-668. PubMed ID: 35481400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
    Kim HD; Kim BJ; Kim HS; Kim JH
    Korean J Intern Med; 2019 May; 34(3):608-617. PubMed ID: 29334722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
    Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
    Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab.
    Xu Y; Yang Y; Li L; Zhou A; Zhang H; Ye F; Zhang W; Zhao H; Zhao X
    Front Oncol; 2022; 12():848129. PubMed ID: 35515116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.